ORIX Down Over 5%, on Pace for Largest Percent Decrease Since November 2022 — Data Talk
ORIX Corporation Sponsored ADR (IX) is currently at $104.37, down $5.83 or 5.29%
--Would be lowest close since March 4, 2024, when it closed at $104.06
--On pace for largest percent decrease since Nov. 7, 2022, when it fell 7.13%
--Currently down six of the past seven days
--Currently down three consecutive days; down 5.5% over this period
--Worst three day stretch since the three days ending Oct. 4, 2023, when it fell 6.9%
--Up 11.76% year-to-date
--Down 34.78% from its all-time closing high of $160.03 on April 4, 2006
--Up 24.84% from 52 weeks ago (April 3, 2023), when it closed at $83.60
--Down 7.33% from its 52-week closing high of $112.62 on March 20, 2024
--Up 27.58% from its 52-week closing low of $81.81 on April 5, 2023
--Traded as low as $104.36; lowest intraday level since March 11, 2024, when it hit $104.35
--Down 5.3% at today's intraday low; largest intraday percent decrease since Nov. 7, 2022, when it fell as much as 7.26%
All data as of 12:04:26 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 01, 2024 12:22 ET (16:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track